Filing Flows › Twist Bioscience (TWST) › Q3 FY26
Twist Bioscience (TWST) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Aug 3, 2026
Twist Bioscience (TWST) reported revenue of $118M for the third quarter fiscal 2026 (Q3 FY26), +23% from a year earlier and +7% from the quarter before. Operating margin was -30.6%, net loss $35.1M (29.6% of revenue).
Twist Bioscience, Q3 FY26: revenue $118M (+23% year over year), operating margin -30.6%, net loss $35.1M, operating cash flow $1.1M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $118M | +7% | +23% |
| Operating profit | −$36.3M | — | — |
| Net earnings | −$35.1M | — | -272% |
| Operating cash flow | $1.1M | — | — |
What changed
Revenue was $118.4M in Q3 FY26, up 23% year over year and up 7% from the previous quarter. NGS applications was the largest line at 52% of revenue. DNA synthesis and protein solutions added $15.8M year over year (up 39%), 71% of the total change.
Operating costs exceeded revenue by $36.3M, an operating margin of -30.6%. Total costs grew 23% against revenue growth of 23%. The fastest-growing cost line was SG&A (+27%). The quarter ended with a net loss of $35.1M, narrower than the previous quarter's $44.0M loss.
Operating cash flow was $1.1M. Non-cash charges added back $6.8M of depreciation and amortization and $18.2M of share-based compensation. Working capital and other items added $11.2M. Capital expenditures of $9.8M exceeded it, leaving free cash flow of −$8.6M.
Questions
What was Twist Bioscience's revenue in the third quarter fiscal 2026?
Twist Bioscience (TWST) reported revenue of $118M for the third quarter fiscal 2026 (Q3 FY26), +23% from a year earlier and +7% from the quarter before.
Was Twist Bioscience profitable in the third quarter fiscal 2026?
Operating loss was $36.3M (-30.6% of revenue) and net loss $35.1M.
Source: Twist Bioscience 10-Q on SEC EDGAR.